Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting

About this update from Nuvectis Pharma, Inc.

[{"type":"image","alt":"Nuvectis Pharma, Inc.","displaySize":"","headline":null,"caption":"Nuvectis Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":152,"url":"https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/W.V.VnmdN5OtxNT977ZzKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/989394dc1a2c2d302d391f5a4d69410d","width":300,"height":152}},"lazy":false},{"type":"text","content":"Fort Lee, NJ, March 26, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced upcoming presentations for NXP900 at the upcoming 2025 American Association for Cancer Research Meeting (2025 AACR), taking place from April 25th to April 30th in Chicago, IL. Presentation details are below:","length":539,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"width:49.04%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Abstract Title","length":14,"tagName":"p","attribs":{}}]},{"style":"width:50.96%;border-top:solid black 1pt;border-right:solid black 1pt;border-bottom:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Poster Presentation Details","length":27,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:49.04%;border-right:solid black 1pt;border-bottom:solid black 1pt;border-left:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"First in human phase 1 trial of the SRC family kinase inhibitor NXP900 in patients with advanced solid tumors","length":109,"tagName":"p","attribs":{}}]},{"style":"width:50.96%;border-right:solid black 1pt;border-bottom:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Session Title First-in-Human Phase I Clinical Trials 2Session Date / Time April 29th, 9:00 AM - 12:00 PM","length":108,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"width:49.04%;border...

More updates from Nuvectis Pharma, Inc.